Nephrogenic systemic fibrosis and gadolinium: A perfect storm

American Journal of Roentgenology

Volumn 191, Issue 4, 2008, Pages 1150-1153

  Colletti, Patrick M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Contrast agent policy; Gadolinium safety; Gadolinium based contrast agents; Nephrogenic systemic fibrosis

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE;

CONTRAST ENHANCEMENT; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FIBROSIS; MAGNETIC RESONANCE ANGIOGRAPHY; NAUSEA AND VOMITING; NEPHROGENIC SYSTEMIC FIBROSIS; NEUROIMAGING; NOTE; OSMOLALITY; PRIORITY JOURNAL; SAFETY; VEIN PUNCTURE; VISCOSITY;

CONTRAST MEDIA; DRUG APPROVAL; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; SKIN DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 53249152011     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.08.1327     Document Type: Note

References (37)

1. Shellock FG, Spinazzi A. MRI safety update 2008: part 1. MRI contrast agents and nephrogenic systemic fibrosis. AJR 2008; 191:1129-1139
2. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108 [Erratum in Nephrol Dial Transplant 2006; 21:1745]
3. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362
4. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008; 43:65-75
5. Sieber MA, Pietsch H. Validity of the animal models for nephrogenic systemic fibrosis. Invest Radiol 2008; 43:338
6. Sieber MA, Walter J, Frenzel T, et al. Are gadolinium contrast agents a possible trigger for the development of nephrogenic fibrosing dermopathy? Eur Radiol 2007; 17(Suppl 1):158
7. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008; 27:955-962
8. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 2007; 188:586-592
9. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27-30
10. High WA, Ayers RA, Chandler J, Zito G, Cowpers SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21-26
11. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56:3433-3441
12. Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007; 2:199-205
13. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR 2008; 190:1060-1068
14. U.S. Food and Drug Administration Website. FDA news: FDA requests boxed warning for contrast agents used to improve MRI images. www.fda.gov/bbs/topics/ NEWS/2007/NEW01638.html. Published May 23, 2007. Accessed May 29, 2008
15. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157
16. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991; 180:85-89
17. Spinosa DJ, Kaufmann JA, Hartwell GD. Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography. Radiology 2002; 223:319-325
18. Le Blanche AF, Tassart M, Deux JF, Rossert J, Bigot JM, Boudghene F. Gadolinium-enhanced digital subtraction angiography of hemodialysis fistulas: a diagnostic and therapeutic approach. AJR 2002; 179:1023-1028
19. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. AJR 2007; 189:1533-1538
20. Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology 1995; 196:439-443
21. Olukotun AY. Safety of MR contrast media. (letter) Radiology 1994; 191:584-585
22. Murphy KP, Szopinski KT, Cohan RH, Mermillod B, Ellis JH. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol 1999; 6:656-664
23. Hieronim DE, Kanal E, Swanson DP. Dosage of gadoteridol and adverse reactions relative to gadopentetate. Am J Health Syst Pharm 1995; 52:2556-2559
24. Greco A, Parker JR, Ratcliffe CG, Kirchin MA, McNamara MT. Phase III, randomized, doubleblind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 2001; 45:457-463
25. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003; 227:639-646
26. Brown JJ, Hynes MR, Wible JH Jr. Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers. AJR 2007; 189:1539-1544
27. Gandhi MJ, Narra VR, Brown JJ, et al. Clinical and economic impact of falsely decreased calcium values caused by gadoversetamide interference. AJR 2008; 190:742; [web]W213-W217
28. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet 2000; 356:1000-1001
29. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3:747-751
30. Bahrami S, Sauk S, Raman S, et al. 10-Year experience with nephrogenic systemic fibrosis: casecontrol analysis of risk factors. AJR 2008; 190[American Roentgen Ray Society 2008 annual meeting abstract suppl]:A9, abstract 031
31. Abujudeh H, Kaewlai R, Kagan A, Asrani A, Nazarian R, Kay J. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in patients receiving gadopentetate dimeglumine: a case series of 24 patients. http://rsna2007.rsna. org/rsna2007/V2007/conference/event_display.cfm?em_id=5012917. Accessed July 7, 2008
32. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001; 42:339-341
33. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5:491-502
34. Saab G, Abu-Alfa A. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration? (letter) AJR 2007; 189[web]:W169
35. American Society of Radiologic Technologists Website. Drug administration by radiologic technologists: resolution 91-4.04. In: Practice issues. https://www.asrt.org/media/pdf/practice_issues.pdf. Published in 1991. Accessed July 8, 2008
36. Parker Waichman Alonso LLP Website. Lawsuit claims GE Omniscan caused nephrogenic systemic fibrosis. http://www.yourlawyer.com/articles/read/13990. Published March 6, 2008. Accessed July 7, 2008
37. Smith JJ, Berlin L. Off-label use of interventional medical devices. AJR 1999; 173:539-542